

Topical Collection

Heterocycles in Drug Discovery

Message from the Collection Editors

Heterocycles are crucial in drug discovery due to their high prevalence in biologically active compounds and pharmaceuticals. These ring structures, containing at least one atom other than carbon (commonly nitrogen, oxygen, or sulfur), constitute a unique opportunity to modulate diverse chemical and physical properties that enhance the interaction with biological targets. Their versatility allows for the design of molecules with improved potency, selectivity, and pharmacokinetic profiles. Many drugs, including antibiotics, antivirals, anticancer agents, and CNS drugs, feature heterocyclic moiety, underscoring their importance in the drug discovery process for developing effective and innovative therapeutics.

Collection Editors

Prof. Dr. Thierry Besson

INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France

Dr. Nicolas Primas

1. CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France
 2. APHM, Pharmacy Department, Service Central de la Qualité et de l'Information Pharmaceutiques, 147 Bd Baille, 13005 Marseille, France
-



Drugs and Drug Candidates

an Open Access Journal
by MDPI



mdpi.com/si/218851

Drugs and Drug Candidates
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ddc@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/ddc)

[ddc](https://mdpi.com/journal/ddc)





Drugs and Drug Candidates

an Open Access Journal
by MDPI



[mdpi.com/journal/
ddc](https://mdpi.com/journal/ddc)



About the Journal

Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peer-reviewed by experts in the field of the work and a first decision will be notified within no more than two weeks. Involved in drug design, drug synthesis, drug evaluation, or drug market, *Drugs and Drug Candidates* is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly Head, Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.